Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Navepegritide in Children and Adolescents With Hypochondroplasia
NCT07917143Phase 3Not yet recruiting
- Sponsor
- Ascendis Pharma
- Start
- Nov 2026
- Primary completion
- Oct 2028
01
Overview
A Phase 3 trial of navepegritide in hypochondroplasia (HCH), sponsored by Ascendis Pharma. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
navepegritide
03
Conditions
hypochondroplasia (HCH)
Beyond the preview
Go deeper on NCT07917143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07917143.